NEWSTRYX NEWS

Royal Family Announces Engagement of Princess Charlotte

Buckingham Palace has announced the engagement of Princess Charlotte to Sebastian Montgomery, the eldest son of the Duke of Rutland, in what royal commentators are calling "the wedding of the decade."

The couple, who met while studying at St. Andrews University, have been dating for three years. The palace statement described them as "delighted" and requested privacy during this special time. The wedding is expected to take place next summer at Westminster Abbey, with a reception at Buckingham Palace.

Mr. Montgomery, 25, works in sustainable energy development and is heir to the Rutland estate in the East Midlands. Royal watchers note this marks the first time a direct descendant of Queen Elizabeth II has married into the British aristocracy since Prince William married Catherine Middleton in 2011.

The announcement has sparked celebrations across the Commonwealth, with crowds already gathering outside Buckingham Palace. Bookmakers are taking bets on everything from the wedding date to the designer of the bride's dress. Security experts estimate the event could cost British taxpayers upwards of £30 million, though tourism officials predict it will generate nearly £500 million in revenue.

Scientists Discover Potential Breakthrough in Alzheimer's Treatment

A team at Cambridge University has identified a new approach to treating Alzheimer's disease that could potentially halt or even reverse cognitive decline in early-stage patients.

The research, published today in Nature Medicine, focuses on targeting specific proteins that accumulate in the brains of Alzheimer's patients. Unlike previous treatments that attempted to remove amyloid plaques, this new approach aims to prevent the formation of toxic oligomers - smaller clusters of proteins that may be more directly responsible for neuron damage.

Early clinical trials involving 120 patients showed promising results, with participants demonstrating improved cognitive function and slowed disease progression. "This isn't a cure, but it could transform Alzheimer's from a terminal diagnosis to a manageable chronic condition," said lead researcher Professor Eleanor Chang.

The pharmaceutical industry has reacted with cautious optimism, with several major companies expressing interest in licensing the technology. However, experts warn that larger phase III trials are needed before the treatment could be approved for widespread use, a process that could take 3-5 years.

Charities supporting Alzheimer's patients and their families have welcomed the news while urging continued funding for research. "This gives hope to millions affected by dementia worldwide," said Sarah Johnson of Alzheimer's Research UK. "But we must remember that today's breakthrough is built on decades of incremental progress."